Posts

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.

/by

Authors: Ester Aso, Isidre Ferrer
Frontiers in Pharmacology, 5 March 2014
—
The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabino…

Read more

A molecular link between the active component of marijuana and Alzheimer’s disease pathology.

/by

Authors: Lisa M. Eubanks, Claude J. Rogers, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, Kim D. Janda
Molecular Pharmaceutics, 2006
—
Alzheimer’s disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer’s disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease p…

Read more